In a filing, MaxCyte Inc revealed its Director Hemrajani Rekha unloaded Company’s shares for reported $22378.0 on Jun 25 ’25. In the deal valued at $2.09 per share,10,684 shares were sold. As a result of this transaction, Hemrajani Rekha now holds 39,893 shares worth roughly $59041.64.
Then, Swirsky Douglas J bought 50,000 shares, generating $64,500 in total proceeds. Upon buying the shares at $1.29, the CHIEF FINANCIAL OFFICER now owns 161,811 shares.
Before that, Masoud Maher bought 75,000 shares. MaxCyte Inc shares valued at $102,915 were divested by the President and CEO at a price of $1.37 per share. As a result of the transaction, Masoud Maher now holds 175,000 shares, worth roughly $0.26 million.
BTIG Research downgraded its MaxCyte Inc [MXCT] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including William Blair’s analysts, who decreased its forecast for the stock in early August from “an Outperform” to “a Mkt perform”. Stephens began covering MXCT with “an Overweight” recommendation on July 22, 2025. Craig Hallum started covering the stock on November 29, 2023. It rated MXCT as “a Buy”.
Price Performance Review of MXCT
On Tuesday, MaxCyte Inc [NASDAQ:MXCT] saw its stock jump 2.07% to $1.48. Over the last five days, the stock has gained 4.23%. MaxCyte Inc shares have fallen nearly -63.00% since the year began. Nevertheless, the stocks have fallen -64.42% over the past one year.
How much short interest is there in MaxCyte Inc?
A steep rise in short interest was recorded in MaxCyte Inc stocks on 2025-08-29, dropping by -0.24 million shares to a total of 3.29 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 3.53 million shares. There was a decline of -7.44%, which implies that there is a negative sentiment for the stock.
